Sander Birgit, Thornit Dorte Nellemann, Colmorn Lotte, Strøm Charlotte, Girach Aniz, Hubbard Larry D, Lund-Andersen Henrik, Larsen Michael
Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Denmark.
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3983-7. doi: 10.1167/iovs.06-1102.
To study the progression of diabetic macular edema (DME) in relation to baseline retinal thickness, retinal vascular leakage, and retinal trunk vessel diameters.
In this single-center study, 45 patients were enrolled with 62 eligible eyes defined as having DME of a grade less than clinically significant macular edema (CSME). From the start, the patients were included in a multicenter study exploring the effect of ruboxistaurin versus placebo for 3.4 years. Subsequently, the patients were followed up for a mean of 5.7 years by optical coherence tomography, fundus photography, and vitreous fluorometry. Baseline values in eyes that progressed to photocoagulation treatment were compared with values from eyes that did not reach this endpoint.
In the 22 eyes of 18 patients in which CSME was diagnosed and treated, mean retinal vascular leakage at baseline was 5.6 (95% CI 4.2-7.6) nm/s, whereas eyes that did not progress to photocoagulation had a significantly lower mean leakage at baseline of 3.4 (95% CI 2.7-4.3) nm/s. No significant difference was found for measures of baseline retinal thickness or summarized retinal trunk vessel diameters. Eyes that progressed to photocoagulation treatment (mean delay to treatment, 3.6 years) had significantly higher foveal thicknesses than did nonprogressing eyes, from 18 months after study initiation.
Progression to photocoagulation treatment for CSME was associated with higher retinal vascular leakage at baseline, whereas baseline retinal vessel diameters and retinal thickness were comparable in progressing and nonprogressing eyes. Baseline leakage was the strongest predictor of progression from non-CSME to photocoagulation for CSME.
研究糖尿病性黄斑水肿(DME)的进展与基线视网膜厚度、视网膜血管渗漏及视网膜主干血管直径之间的关系。
在这项单中心研究中,纳入了45例患者共62只符合条件的眼睛,这些眼睛被定义为患有低于临床显著性黄斑水肿(CSME)级别的DME。从一开始,这些患者就被纳入一项多中心研究,探索鲁比前列酮与安慰剂治疗3.4年的效果。随后,通过光学相干断层扫描、眼底照相和玻璃体荧光测定法对患者进行了平均5.7年的随访。将进展至光凝治疗的眼睛的基线值与未达到该终点的眼睛的值进行比较。
在18例患者的22只眼睛中诊断并治疗了CSME,这些眼睛基线时的平均视网膜血管渗漏为5.6(95%可信区间4.2 - 7.6)nm/s,而未进展至光凝治疗的眼睛基线时的平均渗漏显著更低,为3.4(95%可信区间2.7 - 4.3)nm/s。在基线视网膜厚度测量值或汇总的视网膜主干血管直径方面未发现显著差异。进展至光凝治疗的眼睛(平均治疗延迟3.6年)自研究开始18个月起,其黄斑中心凹厚度显著高于未进展的眼睛。
进展至CSME的光凝治疗与基线时较高的视网膜血管渗漏相关,而进展和未进展的眼睛在基线视网膜血管直径和视网膜厚度方面具有可比性。基线渗漏是从非CSME进展至CSME光凝治疗的最强预测因素。